Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $12.1 million, representing a year-over-year growth of 99% compared to $6.1 million in Q2 2024 [5][11] - Gross margin decreased to 73.4% in Q2 2025 from 75% in Q2 2024, primarily due to expedite production fees and material costs [11][12] - Operating expenses increased to $15.4 million in Q2 2025 from $10.9 million in Q2 2024, with R&D expenses slightly rising to $4.2 million [12][13] - GAAP net loss was $6.8 million in Q2 2025 compared to a net loss of $6.3 million in Q2 2024 [13] Business Line Data and Key Metrics Changes - The company reported 199 surgeon users who completed more than one procedure using the Aprivo technology platform, a 72% increase from the previous year [6] - The average revenue per procedure remained constant at approximately $30,000 [16][39] Market Data and Key Metrics Changes - The total addressable market for Aprivo lumbar spine fusions is estimated to exceed $13 billion, with nearly 4,000 spine surgeons in the U.S. [6] - Recent CMS decisions have enhanced hospital reimbursement for Aprivo procedures, translating to an incremental reimbursement of $20,000 to $50,000 depending on procedure complexity [8] Company Strategy and Development Direction - The company aims to establish a new architecture of surgery to improve patient outcomes and reduce healthcare costs [5] - Plans for a commercial launch of the personalized cervical fusion technology using the Aprivo platform are set for 2026 [10][42] - The company is focused on innovation, including a digital production system that reduces turnaround time for implants from over four weeks to ten business days [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth due to strong surgeon adoption and compelling clinical data supporting the Aprivo technology [11][16] - The company expects to achieve full-year 2025 revenue guidance of $45.5 million to $47.5 million, representing a growth of 67% to 75% over 2024 [16][51] Other Important Information - The company raised $100.5 million in gross proceeds from its IPO, providing sufficient capital to execute its business strategy [14][15] - Cash used in operating activities for the first half of 2025 was $15.2 million, with a monthly average cash burn of $2.5 million [15] Q&A Session Summary Question: Utilization trends in the quarter - Management noted strong uptake in utilization and new surgeon adoption, exceeding internal plans [20][21] Question: Guidance as a new public company - Management highlighted key growth drivers including recent CMS decisions and ongoing innovation [22][23] Question: Procedure adoption and segmentation - The company has seen growth in short construct fusion procedures, expanding from initial targeting of complex procedures [26][27] Question: Seasonality in revenue guidance - Management acknowledged seasonality in procedure volume but did not provide specific Q3 guidance [29][32] Question: Surgeon training and productivity - The company added 47 new surgeons, reaching a total of 199, and plans to continue investing in education programs [34][35] Question: Pricing and revenue guidance - Average revenue per procedure is expected to remain constant, with growth driven by procedure volume [38][39] Question: Cervical launch preparations - The company is preparing for the cervical launch with recent Medicare announcements and technology advancements [42][43] Question: Artificial intelligence costs - Investments in AI are expected to enhance scalability without disproportionately affecting the P&L [44][45] Question: Revenue outlook and surgeon adds - New surgeon additions are expected to drive revenue growth in subsequent quarters [58][60]

TORONTO and DALLAS, Aug. 28, 2025 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, today announced the appointment of Ted James, MD, MHCM, FACS, to the newly created position of Chief Medical Officer ("CMO").In this fractional role, Dr. James will bring his clinical and leadership experience to help Perimeter strengthen its medical strategy and accelerate adoption of its technology. His perspective a ...

Core Viewpoint - The strategic cooperation agreement between Teda Biomedical and Suihong Huachuang Technology aims to leverage each other's resources and technological advantages in the AI healthcare sector, focusing on specialized operations and market promotion of AI medical health and data businesses [1][2]. Group 1: Strategic Cooperation - The partnership will enhance resource and technology synergies, utilizing Suihong Huachuang's established government collaborations and sales channels to support Teda Biomedical's AI medical model and related data business market promotion [2]. - Suihong Huachuang's core technological capabilities in AI computing infrastructure and hardware manufacturing will provide stable and efficient computing power for Teda Biomedical's AI medical model training and real-world application [2]. Group 2: Business Development Focus - Teda Biomedical is actively advancing the research and commercialization of AI medical models and related data businesses, emphasizing the importance of high-quality computing resources, stable hardware solutions, and extensive market promotion channels [1]. - The company plans to engage in resource alignment and cooperation discussions to ensure the sustainable and steady advancement of its business [1].

MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET. A live and archived version of the fireside chat will be available on the Investor Relations sec ...

FORT WORTH, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin markets, today announced that management will present at the Cantor Global Healthcare Conference, which is being held at the New York Marriott Marquis in New York, NY from Sept ...

Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized careSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apn ...

Electromed (ELMD) Q4 2025 Earnings Call August 26, 2025 05:00 PM ET Company ParticipantsMike Cavanaugh - Managing DirectorJim Cunniff - President, CEO & DirectorBrad Nagel - CFOBen Haynor - MD - Medical Technology ResearchConference Call ParticipantsKyle Bauser - MD & Senior Research AnalystAnderson Schock - Medtech Equity Research AnalystOperatorGood day and welcome to the Electromed Fourth Quarter Fiscal Year twenty twenty five Earnings Conference Call. All participants will be in listen only mode. Please ...

Company to Advance Development of its Patented DeviceLAS VEGAS, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products is pleased to provide the following update on the development of its Save A Life (“SAL”) choking rescue device. Odyssey has created a prototype device and now plans to continue the advancement of the product with the ultimate goal of filing a subm ...

  Toronto, Ontario – TheNewswire - August 26, 2025 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”), (TSXV:VPT) announces a non-brokered private placement of up to CDN$500,000 (the “Offering”) of unsecured convertible debenture units (“Units”) subject to TSXV Venture Exchange (the “Exchange”) acceptance. Each Unit will be comprised of one (1) unsecured convertible debenture principal amount of $1,000 (“Debentures”) convertible into common shares (“Common Shares”) of the Corporation, and ...

Company Overview - TransMedics Group, Inc. is a medical technology company focused on transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure [3] - The company is headquartered in Andover, Massachusetts, and is recognized as the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation [3] - TransMedics aims to address the unmet need for more and better organs for transplantation through its developed technologies that preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs [3] Upcoming Events - TransMedics will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 10:00 a.m. EST [2] - The company will also present at the Baird 2025 Global Healthcare Conference on September 9, 2025, at 12:15 p.m. EST [2] - A live and archived webcast of the presentations will be available on the "Investors" section of the TransMedics website [2]